Zhengfa Mao

534 citations
22 papers · 426 indexed · h-index 11
Topics
Pancreatic and Hepatic Oncology Research (7 papers)Cancer Research and Treatments (4 papers)Cancer Mechanisms and Therapy (4 papers)
Partner nations
ChinaCroatiaGermany

In The Last Decade

Zhengfa Mao

21 papers receiving 421 citations

Peers

Zhengfa Mao
Comparison fields: 5 of 56
  • Molecular Biology 265
  • Oncology 155
  • Immunology 103
  • Cancer Research 95
  • Genetics 37
Replace Simona Nuzzo with:
Simona Nuzzo Italy
Benjamin L. Bryson United States
Mary R. Doherty United States
Ilija Crnčec Austria
Totakura V. S. Kumar India
Philip E.D. Chung Canada
Katia Balmas Bourloud Switzerland
Qionghua Zhu China
Wan Rong Qiu United States
Mervi Eeva United States
Zhengfa Mao relative to Simona Nuzzo Italy Simona Nuzzo's profile →
Citations per field
00.5×1.7×
Simona Nuzzo · 1×
Citations per year

Countries citing papers authored by Zhengfa Mao

Since Specialization
Citations

This map shows the geographic impact of Zhengfa Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhengfa Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhengfa Mao more than expected).

Fields of papers citing papers by Zhengfa Mao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhengfa Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhengfa Mao. The network helps show where Zhengfa Mao may publish in the future.

Co-authorship network of co-authors of Zhengfa Mao

This figure shows the co-authorship network connecting the top 25 collaborators of Zhengfa Mao. A scholar is included among the top collaborators of Zhengfa Mao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhengfa Mao. Zhengfa Mao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 10
2 0
3 10
4 13
5 11
6 6
7 7
8
[Mechanism of SPARC-enhanced chemosensitivity of pancreatic cancer cells to gemcitabine].
1
9 11
10 27
11 9
12 16
13 6
14 89
15 27
16 28
17 78
18 41
19 9
20 3

About Zhengfa Mao

Zhengfa Mao is a scholar working on Biotechnology, Oncology and Cancer Research, having authored 22 papers that have together received 426 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (7 papers), Cancer Research and Treatments (4 papers) and Cancer Mechanisms and Therapy (4 papers). The work is most often cited by research in Cancer Research (95 citations), Oncology (155 citations) and Immunology (103 citations). Zhengfa Mao has collaborated with scholars based in China, Croatia and Germany. Frequent co-authors include Xu‐Qing Wang, Dayong Jin, Xin Fan, Yefei Rong, Xiaoyan Ma, Jianguo Qu, Wenchuan Wu, Lei Cui, Jianxin Zhang and Dong Xie. Their work appears in journals such as Gastroenterology, Biochemical and Biophysical Research Communications and Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026